Artificial Intelligence (AI) Collaboration and Licensing Deals 2016-2023

$3,995.00

Artificial Intelligence (AI) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
November 2023
Number of pages
450+
Product type
Research report
Available formats
PDF document
Report edition
2
SKU
CP2125

Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of artificial intelligence deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 863 artificial intelligence deals announced since 2016 including financial terms where available including links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of artificial intelligence dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2016.

Chapter 3 provides an overview of the leading artificial intelligence deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of artificial intelligence deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2016. The chapter is organized by specific artificial intelligence technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in artificial intelligence deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse artificial intelligence collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Artificial Intelligence (AI) Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of artificial intelligence trends and structure of deals entered into by leading biopharma companies worldwide.

Artificial Intelligence (AI) Collaboration and Licensing Deals includes:
•    Trends in artificial intelligence dealmaking in the biopharma industry
•    Directory of artificial intelligence deal records covering pharmaceutical and biotechnology
•    The leading artificial intelligence deals by value
•    Most active artificial intelligence licensing dealmakers

Artificial Intelligence (AI) Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse artificial intelligence collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in artificial intelligence dealmaking
2.1. Introduction
2.2. Artificial intelligence deals over the years
2.3. Most active artificial intelligence dealmakers
2.4. Artificial intelligence deals by deal type
2.5. Artificial intelligence deals by therapy area
2.6. Artificial intelligence deals by industry sector
2.7. Deal terms for artificial intelligence deals
2.7.1 Artificial intelligence deals headline values
2.7.2 Artificial intelligence deal upfront payments
2.7.3 Artificial intelligence deal milestone payments
2.7.4 Artificial intelligence royalty rates

Chapter 3 – Leading artificial intelligence deals
3.1. Introduction
3.2. Top artificial intelligence deals by value

Chapter 4 – Most active artificial intelligence dealmakers
4.1. Introduction
4.2. Most active artificial intelligence dealmakers
4.3. Most active artificial intelligence deals company profiles

Chapter 5 – Artificial intelligence contracts dealmaking directory
5.1. Introduction
5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 – Artificial intelligence dealmaking by technology type

Deal directory

Deal directory – Artificial intelligence deals by company A-Z
Deal directory – Artificial intelligence deals by deal type
Deal directory – Artificial intelligence deals by therapy area

Deal type definitions

About Wildwood Ventures    
Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

Figure 1: Artificial intelligence deals since 2016
Figure 2: Active artificial intelligence dealmaking activity – 2016 - 2023
Figure 3: Artificial intelligence deals by deal type since 2016
Figure 4: Artificial intelligence deals by therapy area since 2016
Figure 5: Artificial intelligence deals by industry sector since 2016
Figure 6: Artificial intelligence deals with a headline value
Figure 7: Artificial intelligence deals with an upfront value
Figure 8: Artificial intelligence deals with a milestone value
Figure 9: Artificial intelligence deals with a royalty rate value
Figure 10: Top artificial intelligence deals by value since 2016
Figure 11: Most active artificial intelligence dealmakers 2016 - 2023
Figure 12: Artificial intelligence deals by technology type since 2016

 

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 3Derm Systems, 3M, 3Sixty, 3Z, 4D Molecular Therapeutics, 4P-Pharma, 23andMe, 111, A*STAR Bioinformatics Institute, A.I. Squared, AbCellera Biologics, Abramson Cancer Center, AbSci, Accelerator for Technological Research in Genomic Therapies, Accuray, Acerand Therapeutics, Actelion, Actuate Therapeutics, Acumen Analytics, AcuraStem, Adapt Analytics, Adaptive Biotechnologies, ADT Altona Diagnostic Technologies, Advata, AdventHealth, Adynxx, AESOP Technology, Aether, Agilent Technologies, AIBody, AiCure, Aidence, Aidoc, Aiforia Technologies, AIG Hospitals, AIkido Pharma, AI Longevity, AI Medical Service, AINQA Health, AIon Labs, Aitia, Aitrics, AIVF, Akon Lighting, Akoya Biosciences, Albany Molecular Research, Alberta Health Services, Albert Einstein College of Medicine, Alexion Pharmaceuticals, Alimentiv, AliveCor, Alliance For Clinical Trials In Oncology, Allosteric Bioscience, Almirall, ALPHA10X, ALS Association, AltaML, Alverno Clinical Laboratories, Amazon Web Services, Amber Pharmacy, American College of Cardiology, American Sleep Apnea Association, American Society of Clinical Oncology (ASCO), Amgen, Amitech Solutions, Analytical BioSciences, Analytics Engines, AnchorDx, Ancora Heart, Antengene, Anthem, Anumana, Aon Group, Aqemia, Aragen Life Sciences, ArcherDX, Arctoris, Ares Genetics, Ariana Pharma, Arm, ArtiQ, ARUP Laboratories, Arvinas, Arzeda, Asensus Surgical, Asimily, Aslan Pharma, Astellas Pharma, Astellas Pharma US, AstraZeneca, Astrogen, Atavistik Bio, AtCor Medical, Athos Therapeutics, Atlazo, ATMPS, Atomica.ai, Atomwise, Augmedix, AUM Biosciences, Auransa, Auron Therapeutics, Automation Anywhere, Avera Health, Avicenna Technology, Axcelead Drug Discovery Partners, Azra AI, BAMF Health, Barcelona Supercomputing Center, BASF, Battelle, Bausch & Lomb, Baxter International, Bayer, Bayer CropScience, Bay Labs, BCG Digital Ventures, BC Platforms, Beacon Biosignals, Beckman Coulter, Becton Dickinson, BeeKeeperAI, BeiGene, Beijing Tide Pharmaceutical, Belle.ai, BenevolentAI, Benson Hill Biosystems, Berg, BERG Analytics, Beyeonics Vision, Bialogics, Bielefeld University, BigHat Biosciences, Bill and Melinda Gates Foundation, BioBright, Biocept, BioDuro, Biofourmis, Biogen, Biogenysis, BioMap, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biorelate, Biosero, BioSig Technologies, BioSymetrics, Biotx.ai, Biovista, Bioz, Bird Foundation, Blackford, BlackThorn Therapeutics, Bloqcube, Blue Earth Diagnostics, Blueprint Medicines, Body Labs, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, BostonGene, Bot Image, BPGbio, Bracco Imaging, Brainomix, BrainScope, Bridge Biotherapeutics, Brigham and Women's Hospital, Bright Giant, Brightseed, Bristol-Myers Squibb, Broad Institute, Brown University, BullFrog AI, BurstIQ, BVI Medical, C2i Genomics, California Institute for Biomedical Research, California Institute of Technology, Calyx, Cambridge Cancer Genomics, Cancer Genetics, CancerLinQ, Cancer Research Horizons, Cancer Research UK, Cannabics Pharmaceuticals, Canon BioMedical, Cardiowise, CareDx, Caresyntax, Caris Life Sciences, Carnegie Mellon University, CAS, CB Scientific, CelerisTx, Celgene, Cellaria Biosciences, Celsius Therapeutics, Centers for Disease Control and Prevention, Centogene, Centre for Imaging Technology Commercialization, Centre Leon Berard, Cerebras Systems, Cerevel Therapeutics, Cerner Enviza, Cernostics, Certis, Certis Oncology Solutions, Charite Universitatsmedizin Berlin, Charles River Laboratories, ChemDiv, Chemical Abstracts Service (CAS), Chemify, Chemi Pharmaceutical, Children's Hospital Boston, Children’s Center for Cancer and Blood Diseases (CCCBD), China Oncology Focus, Christian Doppler Research Association, Circle cardiovascular imaging, City of Hope, CK Life Sciences, Clario, ClariPi, Claritas HealthTech, Clear Medical Imaging, Clearsky Medical Diagnostics, Cleveland Clinic, CLEW Medical, Client Outlook, Clinical Research Strategies, Clinigen, Cloudera, Cloud Pharmaceuticals, CMIC, Cogia Biotech, Cognetivity Neurosciences, Cognoa, Cohen Veterans Bioscience, Colorado Center for Personalized Medicine, Columbia University, ConcertAI, Control Flo Medical, COPD Foundation, CoreBiome, Cortechs.ai, COSBI, Covaris, Crosscope, Crothall Healthcare Technology Solutions, CrystalGenomics, CureMatch, CureMetrix, Cures Within Reach, Curium, Curreio, Current Health, CvergenX, Cyagen Biosciences, Cyclerion Therapeutics, Cyclica, Cyrus Biotechnology, Cytobank, CytoReason, Dacadoo, Daiichi Sankyo, Dana-Farber Cancer Institute, Dante Genomics, Dante Labs, DarwinHealth, Dassault Systems, DataRobot, Datavant, DaVita, DDN, DEARhealth, Debiopharm, Deciphex, Decode Health, DEEP 6 AI, Deep Bio, Deepcell, Deep Cube, Deep Lens, Defense Threat Reduction Agency, Delve Health, DemDx, Denovo Biopharma, Deontics, Department of Defense, Department of Energy, Department of Veterans Affairs, DePuy, Desktop Genetics, DevsHealth, Dewpoint Therapeutics, DiagnaMed, Diagnostic Robotics, DiA Imaging Analysis, DiamiR, Diannei Biotechnology, Digital Diagnostics, Diurnal, doc.ai, DoMore Diagnostics, Draper Laboratories, Drugs for Neglected Diseases Initiative, Duke University, DxS, Dyno Therapeutics, DYO Biotechnologies, e-NIOS, E-Therapeutics, Early Signal Foundation, EchoNous, Edwards Lifesciences, Egnite, Eisai, eKare, Eko, Elemental Machines, Elements of Genius, Eleven Biotherapeutics, Elevian, Eli Lilly, Elix, Elucidata, EmbodyBio, Emerald Innovations, Emory University, Empirico, Enamine, Endocanna Health, Endoluxe, Endpoint Health, EndPoint Technologies, Envisagenics, Envista, EpiAxis Therapeutics, EQRx, ETH Zurich, European Board and College of Obstetrics and Gynaecology, Evaxion Biotech, Evidation Health, Evotec, Ewha Womans University, Exactech, Excelra, Exigent Research, EXINI Diagnostics, Experimental Drug Development Centre, ExpreS2ion Biotechnologies, ExScientia, Fabric Genomics, Facit, FAR Biotech, Farcast Biosciences, FDNA, Ferring Pharmaceuticals, Ferrum Health, Finnish Institute for Health and Welfare, Fio, FK LiveLabs, Flo Health, Focal Healthcare, Food and Drug Administration (FDA), Fosun Pharmaceutical, Foundation for Neglected Disease Research, FOXO Technologies, Freenome, Fujifilm Irvine Scientific, Fujifilm medical systems, Fujitsu Laboratories, Fujitsu Laboratories of America, Fulgent Genetics, Fusion Antibodies, G42 Healthcare, Galecto, Galmed Pharmaceuticals, Gandeeva Therapeutics, GATC Health, Gatehouse Bio, GC Pharma, GDM Seeds, GE Healthcare, Geisinger Health System, Genea Biomedx, Genentech, General Genomics, Generate Biomedicines, Genesis Therapeutics, Genetica, Genetic Leap, Geneva University Hospitals, Genialis, Genomics, Genomics England, Genoox, Genpact, Genzeva, Georgia Institute of Technology, German Heart Centre Berlin, Gero, Gestalt Diagnostics, Getinge, Gilead Sciences, Ginkgo BioWorks, GlamorousAI, Glassbeam, Global Alzheimer's Platform (GAP), Global Good Fund, Gnosis Bioresearch, GNS Healthcare, Google, Govzilla, Gray Matter, Gretel, Grifols, GSK, GSK Consumer Healthcare, GT Apeiron Therapeutics, Hackensack Meridian Health, Halberd, Halo Dx, Hapbee Technologies, Happify Health, Happy Life Tech, Harvard University, Hatchleaf, Haystack Health, HCA Healthcare, Healint, HealthCare Konnect, HealthLytix, HealthPointe Solutions, Health Recovery Solutions, HealthTrio, Healx, HeartSciences, Helio Health, Helmholtz Zentrum Munchen, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, HemoShear, Henry M. Jackson Foundation, HistoIndex, HistoWiz, Hitachi, Holmusk, Hologic, Horizon Discovery, Hospital of University of Strasbourg, HotSpot Therapeutics, HTG Molecular Diagnostics, Huawei, Huma, Humana, Human Longevity, Hyfe, I-mab, Ibex Medical Analytics, iBio, IBM, IBM Watson Health, iCAD, Icometrix, IDx, Ikonisys, Ikonopedia, Iktos, Illumina, Image Analysis, ImageBiopsy Lab, Imagia Cybernetics, Imbio, Immucor, Immuneering, ImmunoPrecise Antibodies, Inari Medical, Indica Labs, Indivumed, Industrial Centre for Artificial Intelligence Research in Digital Diagnostics, IndyGeneUS AI, Inform Diagnostics, Ingenza, InnerScope Hearing Technologies, Innoplexus, Innovate UK, Inova Translational Medicine Institute, Insel Gruppe, Insilico Biotechnology, Insilico Medicine, InSilicoTrials, Insitro, Institut Bergonie, Institut Carnot CALYM, Institut Curie, Institute for Molecular Medicine Finland, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Cancer Research, Institut Gustave Roussy, Institut Kanser Negara, Institut Pasteur, Integra LifeSciences, Intel, Intellegens, IntelliTek Health, Interprotein, InterSystems, Invaryant, InveniAI, inviCRO, Ionis Pharmaceuticals, IQVIA, iSiP, Israeli National Authority for Technological Innovation, Iterative Health, Iterative Scopes, JADBio, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Agency for Medical Research and Development, J Craig Venter Institute, Jewish General Hospital, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Johns Hopkins University, John Snow, Johnson & Johnson, Johnson & Johnson Innovation, John Wiley and Sons, Juvenescence, Kadmon Pharmaceuticals, Kaiser Permanente, Kallyope, Kangaroo Health, Karuna Therapeutics, KBP BioSciences, Kebotix, Kempelen Institute of Intelligent Technologies, KemPharm, KeyWise, Khalpey AI Lab, Kheiron Medical Technologies, Kings College London, Kirin, Konica Minolta, KX, KYAN Therapeutics, Kyoto University, Kyowa Hakko Kirin, L'Oreal, Laboratory Corporation of America, Labrador Technologies, LabTwin, La Jolla Institute for Allergy & Immunology, Lantern Pharma, Lark Technologies, Les Laboratoires Servier, Libera Bio, Lieber Institute, LifeArc, Lifebit Biotech, Limbus AI, Lirio, LMU University Hospital Munich, Lochan, Lokavant, Long Island University, Loop Insights, Lumen Biomedical, Lunaphore, Lundbeck, Lunit, M2Gen, MAbSilico, Maitri Health Technologies, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Massive Bio, Mateon Therapeutics, Max-Planck, Mayo Clinic, Mayo Clinic BioPharma Diagnostics, McGill University, MD Anderson Cancer Center, Medable, Medcase, Medial, Medial EarlySign, MEDIAN Technologies, Medical iSight, Medical University of Graz, Medicines and Healthcare Products Regulatory Agency, Medidata Solutions, Medipath, MediTechnix, Medopad, MedRhythms, Medtronic, MedyMatch, Melax Technologies, Memorial Sloan Kettering Cancer Center, Mendel Health, Menten AI, Merck and Co, Merck KGaA, Mesh Bio, Michael J Fox Foundation, Michigan State University, Micronoma, Microsoft, MILA International, Milner Therapeutics Institute and Consortium, MindPeak, MindRank AI, Mindstrong Health, MITRE, Mitsubishi Tanabe Pharma, Mitsubishi UFJ Capital, Mitsui, Moderna, Mohamed bin Zayed University of Artificial Intelligence, Mohammed VI Polytechnic University, Molcure, Molecular Health, Molecule.one, Moleculera Labs, Monsanto, MORE Health, Moss Genomics, Motic, Mount Sinai Health System, MSAID, MultiOmic Health, Multiple Sclerosis Society of Canada, Mundipharma, MyClearStep, MyHealios, Myovant Sciences, Myriad Genetics, Mytide Therapeutics, Nano-X Imaging, Nanoform, Nano Global, NanoTemper Technologies, Nantes University, Nashville Biosciences, National Cancer Center of Japan, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of General Medical Sciences, National Institute of Standards and Technology, National Institute on Aging, National Institutes of Health, National Kidney Foundation, National Research and Innovation Agency of Uruguay, National Science Foundation, National Taiwan University Hospital, National University of Singapore, Naval Medical Research Center, NEC, Neiman Institute, Neochromosome, Neosoma, NeoX Biotech, Nestle, NetraMark, NeuroLogica, NeuroLucent, Neurophth Therapeutics, Neuropore Therapies, New England Biolabs, New Jersey Innovation Institute, Neximmune, Nference, NHS Scotland, NIMML Institute, NImmune Biopharma, Ninety One, Nonacus, Northeastern University, Northwestern Medicine Bluhm Cardiovascular Institute, Northwestern University, Norwegian Research Council, Novarad, Novartis, Novo Nordisk, NRG Oncology, NTT Data, NTx, Nuance Healthcare, Nucleai, NuMedii, Numerate, NuProbe, Nuritas, Nurosene, NuvoAir, Nvidia, NWO.ai, NYU Langone Medical Center, ObvioHealth, Ocean Spray Cranberries, Ohio State University, OmGeneum, OmiCure, Omix Technologies, Omron, Oncode Institute, Oncodesign, OncoHost, OncoStatyx, Oncotelic, One Drop, Onegevity, One GI, OneThree Biotech, OnKai, Ono Pharmaceutical, Ontario Institute for Cancer Research, OpenAI, OpenBench, Open Commons Consortium, OpenFold Drug Discovery AI Research Consortium, OphtAI, Optellum, Optibrium, Optomed, OptraHEALTH, Ordaos Bio, Oregon Oncology Specialists, OrganX, Ori Biotech, Origenis, Orion Genomics, OSE Immunotherapeutics, Oslo University Hospital, Otsuka, Outpace Bio, Owkin, Oxford Sciences Innovation, Pacific Biosciences, Pacific Dental Services, Paige, Palantir, Pancreatic Cancer Collective, PAQ Therapeutics, Paragon Bioservices, Parallax Health Sciences, Parexel, Partex Group, PathAI, Pathway Genomics, PEAR Therapeutics, Penn Medicine, Penumbra, PeptiDream, Peptilogics, Peptone, PercayAI, PeriGen, PerkinElmer, Perthera, Pfizer, PGI Drug Discovery, PharmAI, Pharmarack, PharmaTher, PharmEnable, Pharnext, Phenome Networks, PhoreMost, Phylloceuticals, PicnicHealth, Pieces Technologies, Ping An Ventures, Pioneering Medicines, Pirche, Plex Research, Pluristem Therapeutics, PolarisQB, Policlinico Gemelli, Porton Pharma Solutions, PostEra, PPD, Pramana, Predictive Oncology, Preferred Networks, Premier Health Group, Premier Research, Prenosis, Prescient Medical, PrimeVigilance, PRISM BioLab, Procter & Gamble, Prognos, ProofPilot, Prophase Labs, Proscia, Protagen, Proteic Bioscience, Proteona, Proteovant Therapeutics, Protxx, PsychoGenics, Pumas-AI, Qiagen, Qlarity Imaging, Qu & Co, QuantHealth, Quantiphi, Quantum-Si, Queen Mary University of London, Queens University Belfast, Quest Diagnostics, QurAlis, Qure.ai, Quris-AI, R1 RCM, RadImageNet, RadNet, Rady Children's Institute for Genomic Medicine, RapidAI, RARE-X, RayBiotech, ReadCoor, Recursion, Regard, RegenLab, Regenstrief Institute, Reified Capital, Reified Labs, Rejuve.AI, Related Sciences, Relation Therapeutics, Relay Medical, Relief Therapeutics, Reliq Health, RenalytixAI, Repare Therapeutics, Repurpose.AI, Reputable Health, Research Institute of McGill University Health Centre (RI MUHC), RetinAI Medical, Reveal Biosciences, RevealDx, Reverie Labs, Revive Therapeutics, RevolKa, Revon Systems, Rhythm Pharmaceuticals, RIKEN Research Institute, Riverain Medical, Roche, Roche Diagnostics, Rockley Photonics, Rohto Pharmaceutical, Roux Institute, Royal Philips Electronics, Rush University Medical Center, Rutgers University, Ryailti, Saama, Saitama Medical University Hospital, Salud Digna, Salud Interactiva, Samsung Electronics, Sana Klinikum Offenbach, Sanofi, Santen, Sanuwave Health, Sartorius, SAS, Satisfai Health, Savana, Schrodinger, SCIMAGE, Scopio Labs, Screenpoint Medical, Scripps Research Institute, Second Genome, Sectra, See-Mode Technologies, Seedo, Segmed, Sema4, Semmelweis University, Sensyne Health, Serenus.AI, Seven Bridges Genomics, Shanghai Accurature Diagnostics, Shape Therapeutics, Shenzhen Semacare Medical Technology, Shionogi, Siemens Healthineers, Silexon, SilverCloud Health, Simulations Plus, Sinopia Biosciences, Sirona Dx, Sirona Medical, SK Biopharmaceuticals, SkylineDX, Slovak University of Technology, SmartAction, Snowflake, Socionext, SOINN, Soli Organic, SomaLogic, SOM Biotech, SonoScape Medical, Sonrai Analytics, SOPHiA Genetics, Soricimed Biopharma, Sosei Heptares, SOTERIA Precision Medicine Foundation, Southern Oncology Specialists, Spanish National Cancer Research Centre, Spark Biomedical, Spesana, SRI International, St. Lukes Health System Clinically Integrated Providers, Standigm, Stanford University, Stanford University School of Medicine, Stem of Hope, StemoniX, Stratus Research Labs, Subtle Medical, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Sun Pharma Advanced Research Company, Susan G. Komen for the Cure, Sybleu, SymphonyAI, Syneos Health, Syngenta, Synopic, Syntegra, Tachyum, Taisho Pharmaceutical, Takeda Pharmaceutical, Talem Therapeutics, Talus Bioscience, TARA Biosystems, TB Alliance, Techcyte, Teijin, Telix Pharmaceuticals, TELUS Ventures, Tempus, Tencent Holdings, TenX Biopharma, TeraRecon, Teva Pharmaceutical Industries, TheraPanacea, Therapixel, Therma Bright, Thermo Fisher Scientific, The Technical University Of Munich, The University of Chicago Medicine, ThinkCyte, ThirdEye, Tissue Analytics, Tokyo Medical and Dental University, Topcon, TOPIC Embedded Systems, Total Brain, Totus Medicines, Transgene, Translational Drug Development, Transtoxbio, Treatment.com International, Trethera, Tribun Health, TruDiagnostic, TTC, TTP Group, Turbine, Twist Bioscience, twoXAR, UCB, UiPath, UK Government, Ultima Genomics, Ultivue, UltraSight, UMass Memorial Medical Center, Unilabs, United Imaging Healthcare, Universite Laval, University Gastroenterology, University Health Network, University Medical Center Utrecht, University of Augsburg, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of California Santa Barbara, University of Chicago, University of Connecticut, University of Dundee, University of Edinburgh, University of Hong Kong, University of Leuven, University of Ljubljana, University of Maryland Baltimore, University of Miami, University of Michigan, University of Milano-Bicocca, University of Minnesota, University of Missouri, University of Montreal, University of New South Wales, University of North Carolina, University of Notre of Dame, University of Oxford, University of Pittsburgh, University of Quebec, University of Sherbrooke, University of Stuttgart, University of the Highlands and Islands, University of Tokyo, University of Toronto, University of Tubingen, University of Utah, University of Washington, University of Zurich, Unlearn, UPMC, Us2.ai, Usynova Pharmaceuticals, Utah Genome Project, UW Medicine, Valeant Pharmaceuticals, Valence Discovery, Valisure, Valo Health, Vanderbilt University, VantAI, Vapotherm, Varian Medical Systems, Vastrax, Vectura, Velsera, Veracyte, Verantos, Verb Surgical, Verge Genomics, Verily, VeriSIM Life, Verne Global, Vertex Pharmaceuticals, Vidence, VieCure, Vir Biotechnology, Virginia Commonwealth University, Virgo Surgical Video Solutions, Visage Imaging, Visiopharm, VistaPath, VisualDx, Vitaccess, Viva Biotech, Viviphi, Viz.ai, Volastra Therapeutics, Volpara Solutions, Volpi, VUNO, Vyant Bio, Vysioneer, WakeMed Health & Hospitals, Ward Medication Management, Washington University in St Louis, Weill Cornell Medical College, Weizmann Institute, WhiteLab Genomics, Whiterabbit, Windber Research Institute, WinterLight Labs, Wipro, Worldwide Clinical Trials, Worthington Biochemical Corporation, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, Wyss Institute, X-chem, Xanadu, xCures, XtalPi, Yale School of Medicine, Yitu Medical, Yuhan Corporation, ZebiAI Therapeutics, Zebra Medical Vision, Zephyr AI

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.